Challenge with mammary tumor cells expressing MHC class II and CD80 prevents the development of spontaneously arising tumors in MMTV-neu transgenic mice

被引：0
作者：
N Jabrane-Ferrat
M J Campbell
L J Esserman
B M Peterlin
机构：
[1] Institut de Sciences et Technologies du Medicament de Toulouse,Department of Surgery
[2] CNRS-Pierre Fabre,Department of Medicine
[3] University of California,undefined
[4] Rosalind Russell Medical Research Center,undefined
[5] University of California,undefined
来源：
Cancer Gene Therapy | 2006年 / 13卷
关键词：
breast cancer; immunity; costimulation; MHC class II; CIITA;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
The HER-2/Neu oncogene has been implicated in human and mouse breast cancer. Indeed, transgenic MMTV-neu mice expressing this oncogene from the mammary tumor virus long terminal repeat develop spontaneous mammary tumors and die within 1 year of life. We have expressed the class II transactivator (CIITA) and/or the costimulatory molecule CD80 (B7.1) in a mammary carcinoma cell line (MCNeuA) derived from these mice. Class II transactivator directs the expression of MHC class II and the machinery for antigen processing and presentation by this pathway. When injected into MMTV-neu mice, tumor cells expressing CD80 or CD80 and CIITA, were rejected completely. In addition, following the rejection of dual expressing cells, 75% of the mice were protected against the development of subsequent spontaneous tumors. Cells expressing only CD80 or CIITA were not as effective as antitumor vaccines in preventing the development of spontaneous tumors. Thus, converting cancer cells into antigen presenting cells could represent an effective immunotherapy for breast cancer.
引用
收藏
页码：1002 / 1010
页数：8
相关论文
共 216 条
[1]  
Allison JP(1994)CD28-B7 interactions in T-cell activation Curr Opin Immunol 6 414-419
[2]  
Bour-Jordan H(2002)CD28 function: a balance of co-stimulatory and regulatory signals J Clin Immunol 22 1-7
[3]  
Blueston JA(2002)The B7 family of ligands and its receptors: new pathways for co-stimulation and inhibition of immune responses Annu Rev Immunol 20 29-53
[4]  
Carreno BM(2003)Modulation of co-stimulation to enhance tumor immunity Cancer Immunol Immunother 52 663-669
[5]  
Collins M(1992)Co-stimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4 Cell 71 1093-1102
[6]  
Vesosky B(1994)Tumor immunogenicity determines the effect of B7 co-stimulation on T cell-mediated tumor immunity J Exp Med 179 523-532
[7]  
Hurwitz AA(1994)B7-1/CD80-transduced tumor cells elicit better systemic immunity than wild-type tumor cells admixed with Corynebacterium parvum Cancer Res 54 5420-5423
[8]  
Chen L(1999)Anti-tumor immunity generated by tumor cells engineered to express B7-1 via retroviral or adenoviral gene transfer Cancer Lett 135 1-10
[9]  
Ashe S(1998)Enhancement of the anti-tumor immune response using a combination of interferon-gamma and B7 expression in an experimental mammary carcinoma Int J Cancer 77 107-113
[10]  
Brady WA(2000)Vaccination with mouse mammary adenocarcinoma cells coexpressing B7-1 (CD80) and B7-2 (CD86) discloses the dominant effect of B7-1 in the induction of antitumor immunity J Immunol 164 698-704
12345678910